Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment

This computational brain modelling study (n=42) compared how psilocybin (25mg; 2x) and escitalopram treatments affect brain hierarchy and neural plasticity in depressed patients. It found that psilocybin increased brain susceptibility to change while escitalopram reduced it, though both treatments promoted transitions towards healthier brain states.

Abstract of Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment

Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distinct brain states, with implications for neuropsychiatric disorders. Here, we first explore how whole-brain models, guided by the thermodynamics of mind framework, estimate brain hierarchy and how perturbing such models enables the study of in-silico transitions represented by static functional connectivity. We then apply this to major depressive disorder, where different brain hierarchical reconfigurations emerge following psilocybin and escitalopram treatments. We build resting-state whole-brain models of depressed patients before and after interventions and conduct a dynamic sensitivity analysis to explore brain states’ susceptibility—measuring their capacity to change—and their drivability to healthier states. We show that susceptibility is on average reduced by escitalopram and increased by psilocybin, and that both treatments promote healthier transitions. These results align with the post-treatment window of plasticity opened by serotonergic psychedelics and the similar clinical efficacy of both drugs in trials. Overall, this work demonstrates how whole-brain models of brain hierarchy can inform in-silico neurostimulation protocols for neuropsychiatric disorders.

Authors: Marcel Socoró-Garrigosa, Yonatan Sanz Perl, Morten L. Kringelbach, David Erritzoe, David J. Nutt, Robin Carhart-Harris, Jakub Vohryzek & Gustavo Deco

Summary of Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment

The article explores how the brain represents information and how this representation changes in neuropsychiatric conditions like major depressive disorder (MDD). Traditionally, neural representation was thought to occur at the level of individual neurons or small groups of cells, with classic examples including place cells in the hippocampus and orientation-selective cells in the visual cortex. However, recent advancements in neuroimaging, particularly functional MRI and magnetoencephalography, have enabled the study of distributed brain activity across larger networks. This shift has introduced the concept of the connectome—a map of neural connections—and has shown that the brain exhibits small-world properties and modular organisation, suggesting a balance between local processing and global integration.

This broader perspective challenges the idea of localised representation and suggests that information may be encoded in hierarchical, distributed networks. Measures such as functional connectivity (FC) and structural connectivity (SC) have identified disruptions in network dynamics in conditions such as Alzheimer’s disease, schizophrenia, PTSD and MDD. Despite their utility, these measures remain descriptive and do not explain how structure produces function. Whole-brain models address this limitation by simulating the interaction of brain regions based on anatomical connectivity and local dynamics. These models are personalised using individual neuroimaging data and can simulate transitions between different brain states, offering insight into causality and adaptability in neural systems.

The authors incorporate the thermodynamics of mind framework into these models, allowing them to estimate the hierarchy of causal influences by examining asymmetries in information flow. Hierarchical systems break a physical principle known as detailed balance, producing neural signals that are irreversible in time. This irreversibility serves as a marker of functional hierarchy and is quantified using temporal asymmetry between time-shifted signals. These features are integrated into generative effective connectivity (GEC) models, which simulate directional and hierarchical dynamics. The authors also apply dynamic sensitivity analysis—a technique for assessing how brain states respond to in-silico perturbations, such as simulated stimulations—to study transitions between depressive and healthier brain states.

To access this content, you must purchase one of the following memberships: Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment

https://doi.org/10.1111/nyas.15391

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Socoró‐Garrigosa, M., Perl, Y. S., Kringelbach, M. L., Erritzoe, D., Nutt, D. J., Carhart‐Harris, R., ... & Deco, G. (2025). Perturbing whole‐brain models of brain hierarchy: An application for depression following pharmacological treatment. Annals of the New York Academy of Sciences.

Study details

Compounds studied
Psilocybin Placebo

Topics studied
Depression Neuroscience

Study characteristics
Original Re-analysis Placebo-Controlled Double-Blind Randomized Bio/Neuro

Participants
42 Humans

Compound Details

The psychedelics given at which dose and how many times

Psilocybin 25 mg | 2x

Linked Research Papers

Notable research papers that build on or are influenced by this paper

Trial of Psilocybin versus Escitalopram for Depression
This double-blind placebo-controlled study (n=59) compared psilocybin (2x25mg; 3 weeks apart) to escitalopram (SSRI) over a six-week period and found large improvements in depression scores for those suffering from depression (MDD) in both groups. On the main measure of depression, the QIDS-SR-16, there was no significant difference between both groups. The study did find significant differences, favoring psilocybin, on the HAM-D-17, MADRS, avoidance, flourishing, wellbeing, and suicidality.

Linked Clinical Trial

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the SSRI (selective serotonin reuptake inhibitor) escitalopram for major depressive disorder (MDD).

PDF of Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment